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Galactan-binding myeloma proteins (GalBMP) 1 of BALB/c mice form a family of 
closely related immunoglobulins characterized by VK4 L chains and VII 1B H chains 
(see ref.  1 for  classification). The  V  regions  of four of these  proteins  have  been 
completely sequenced  (2-4).  Three VK4 regions, XRPC24  (X24), XRPC44  (X44), 
and TEPC601  (T601), are identical up to position 95, whereas J539 VK4 differs at 
five positions. Each L chain has a different Jk region (4). In the VH region, X44 and 
T601 are identical up to position 96, but X24 differs from both at three positions (37, 
45, and 53). J539 has seven VH differences from X24 and four each from X44 and 
T601. All four H  chains differ in D and J  region sequences (3). 
In  previous  studies  (5-7),  we  have  shown  that  idiotypic antisera  to  individual 
GalBMP such as X24, X44, and J539 can be raised in strain A/J mice. We have also 
identified two cross-reacting idiotopes. T601, X24, and X44 proteins share a common 
idiotope, J539 and X44 share another. The availability of the primary structures of 
the four GalBMP makes it possible to identify the amino acids that determine these 
idiotopes. In addition, hypothetical three-dimensional models of GalBMP have been 
developed (8) that permit localization of the determining amino acids on the surface 
topography of the GalBMP. 
Monoclonal anti-idiotypic antibodies enable us to further define the structure of 
these idiotopes, particularly when several determining amino acids are implicated. 
The interaction of homogeneous antibody with multiple sites on the antigen defines 
contact points for the antibody and outlines the topographical region of complemen- 
tarity.  Also,  when  the  idiotope is  associated with  the  antigen binding site of the 
antigenic molecule, hapten inhibition studies can be useful in localizing the idiotypic 
site.  In the present study, we describe a monoclonal antibody, HyX24-14, produced 
by the Kohler-Milstein methodology (9) that binds different GalBMP with different 
affinities. Using amino acid sequence data and hypothetical topographical models, 
the  binding  size for  this  monoclonal  antibody on  the  GalBMP  can  be  partially 
outlined. 
1 Abbreviations used in  this paper: BSA,  bovine serum  albumin;  DMEM,  Dulbecco's minimal essential 
medium; GalBMP, galactan-binding myeloma protein; HBSS, Hanks' balanced salt solution; HT, hypo- 
xanthine thymidine medium; PBS,  phosphate-buffered saline; PEG, polyethylene glycol;  RIA, radioim- 
munoassay. 
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Materials  and  Methods 
Animals.  Strain A/J mice were used for immunization and (BALB/c X A/J)F1 (CAF  0 mice 
were used for ascites production and as a source of thymocytes. Both strains were obtained from 
National Cancer Institute contract N01-CB-94326 at Litton Bionetics, Inc., Kensington, Md. 
Immunizations.  The production of anti-idiotypic antisera has been described previously (6). 
Briefly, strain A/J mice were injected with 400-600 #g NH2SO4 precipitate of XRPC24 ascites. 
In the first injection, the antigen was mixed with complete Freund's adjuvant, the second with 
incomplete Freund's adjuvant, and the third with saline, each given subcutaneously 5 d apart. 
Three more subcutaneous injections in saline were given 2 wk apart and the last boost of the 
antigen was injected intravenously in saline 6 wk later. 
Fusion.  3 d after the last antigen injection, the mouse was bled out and its spleen cells were 
used for fusion with Sp 2/0-Ag cells (9, 10). Sp 2/0-Ag cells were grown in "full medium", i.e., 
Dulbecco's minimal essential medium (DMEM), 25 mM glucose, 25 mM Hepes buffer, 2 mM 
glutamine, 50 U/ml penicillin/streptomycin (all reagents from M. A. Bioproducts, Walkersville, 
Md.),  2  ×  10  -5 M  2-mercaptoethanol  (Aldrich Chemical  Co.,  Milwaukee, Wis.)  and  10% 
newborn calf serum  (Gibco Laboratories, Grand  Island, N.  Y.).  8-azaguanine, with a  final 
concentration 1.3 ×  10  -4 M  (Calbiochem-Behring Corp., San Diego, Calif.) was added to full 
medium for growth of the Sp 2/0-Ag tumor cells, to prevent revertants at the hypoxanthine- 
guanine-phosphoribosyl transferase (HGPRT) locus. After separately washing Sp 2/0-Ag and 
spleen cells twice in Hanks' balanced salt solution (HBSS) containing 10 mM Hepes (M. A. 
Bioproducts), cells were mixed in DMEM with 25 mM Hepes at a ratio of 6.5 nucleated spleen 
cells to one tumor cell, spun for 10 rain at 190g, and then fused at 37°C by gently resuspending 
the cell pellet in 0.5 ml autoclaved 45% (wt/vol) polyethylene glycol (PEG)  1,000 (J. T. Baker 
Chemical Co., Phillipsburg, N. J.) in HBSS. After 1 min, the cell PEG mixture was diluted by 
dropwise addition of 10 ml DMEM, 25 mM Hepes over the next 5 min. Cells were spun down 
and cultured overnight in 50 ml full medium plus 1.6 ×  10  -s M hypoxanthine and 1 ×  10  -4 M 
thymidine (Sigma Chemical Co., St. Louis, Mo.) (HT medium) in a tissue culture flask (3150; 
Costar, Data Packaging, Cambridge, Mass.). The following day, 125 ml of HT medium and 
aminopterin (Sigma Chemical Co.) was added to a  final concentration of 4  ×  10  -7 M. Cells 
were cultured in 24-well tissue cultiare plates (3524;  Costar) at -1.25 X  106 spleen cells/1.25 ml 
culture. Cultures were fed at day 6 with  1 ml HT medium plus aminopterin. At day 11,  1 ml 
supernatant was exchanged for 1 ml HT medium. 
Cloning.  Cells of antibody-positive hybrid cultures  were  cloned  by  limiting dilution  in 
suspension cultures in 96-well tissue culture plates (3596;  Costar) in HT medium with 1 ×  106/ 
ml mouse thymocytes as the feeder layer. After 11 d, single growing clones were identified and 
marked  under  a  dissecting microscope, clones were  fed  with  100  #1  full  medium,  and  the 
supernatants  were  analyzed for the presence of antibody 2-3  d  later.  Positive clones were 
transfered to 1-ml cultures with fresh thymocytes in full medium. One representative clone of 
each original hybrid culture was subcloned and afterwards maintained in continuous passaging 
in  l-ml ~zultures. Aliquots were frozen and kept in liquid nitrogen. 
Ascites Production.  After two cloning cycles, cells were grown up in tissue culture flasks and 
1 ×  105-1  ×  106  washed  cells were  injected  into  8-16-wk-old CAFa  mice.  Mice had  been 
conditioned 4-8  wk  earlier by intraperitoneal  injection of 0.5  ml  pristane  (2,6,10,14-tetra- 
methylpentadecane; Aldrich Chemical Co.). Rapidly growing intraperitoneal tumors developed 
after 12-20 d and 5-15 ml ascites fluid could be drained from each mouse. 
Radioimmunoassays (171,4).  All RIA were performed as solid-phase RIA in 96-well flexible, 
polyvinyl chloride microtiter plates (1-220-25;  Dynatech Laboratories, Inc., Alexandria, Va.) in 
two variations of a previously described procedure (11,  12). 
(a) For detecting antibody in tissue culture supernatants, a direct binding assay was applied. 
Microtiter plates were coated overnight with  100 pl/well of a  mixture of rabbit anti-mouse 
immunoglobulin sera diluted in phosphate-buffered saline (PBS), pH 7.4. After emptying the 
plates, 50-100 pl of tissue culture supernatant was added and the plates were incubated for 1- 
2 h at 37°C, washed three times with 1% bovine serum albumin (BSA) in PBS, pH 7.4 (BSA- 
PBS), and then 100/tl of 125I-labeled X44 IgA myeloma protein at 50,000 cpm diluted in BSA- 
PBS was added. After 1-2 h of incubation at 37°C and  10 washes in tap water, the wells were 
cut  out  and  radioactivity was counted  in  a  Beckman  counter  (Beckman  Instruments,  Inc., 1948  IDIOTOPES OF GALACTAN-BINDING MYELOMA  PROTEINS 
Fullerton,  Calif.).  Hybridoma culture  fluids binding more than  three  times  the counts  per 
minute of control cultures without  growing hybridomas were considered positive for mouse 
IgM or IgG with a-X44 activity. The heavy chain class of a  given hybridoma antibody was 
determined by using the rabbit antisera individually. 
(b) In competition assays, the plates were coated with 100/tl of diluted antiserum or ascites 
or 0.5 #g purified myeloma proteins and washed three times with 1% BSA. 20 #1 of competitor 
diluted in 1% BSA-PBS (50,000 cpm) of t25I-iabeled myeloma or hybridoma protein was then 
added and incubated for 8-16 h at 37°C. Each competitor concentration was run in triplicate 
and the percent control binding was calculated as 
cpm competitor -  cpm background 
×  100. 
cpm BSA -  control -  cpm background) 
The various competition systems are identified by first  the name of the reagent coated to the 
plate and then the xzsI-labeled taget; e.g.,  the a-T601/X24 system used an a-T601 serum on 
the plate and 126I-X24  as the target. 
(c) Four rabbit antisera, each raised against a purified myeioma protein, Or, x),  (-/~), 0'2~), 
and  (y31¢) were made immunoglobulin class specific by extensively absorbing them over two 
Sepharose-4B  immunoadsorbent  columns, one coupled with  a  Bence-Jones protein  and  the 
other with the myeloma protein X24 (IgA, k). Testing in direct binding RIA with 125I-labeled 
myeloma  proteins  of various  H  chain  classes  showed  them  to  be  exclusively  specific  for 
individual mouse immunoglobulin heavy chain classes. 
(d) Iodination of protein with 12sI was performed as previously described (12). 
(e)  Hapten  inhibition  was determined  in  microtiter wells  coated with  100 #1 of 5 #g/ml 
purified GalBMP in PBS solution. Haptens diluted in 0.1% BSA-PBS were used as competitors 
and xssI-HyX24-14  was used as the target following the same procedure as described for the 
competition RIA. Cellobiose and O-methyl-/3-v-galactopyranoside were both purchased from 
Sigma Chemical Co./3-1,6-D-galactodiose and/3-1,6-D-galaetotriose were synthesized by Apurba 
et al.  (13) and kindly supplied to us by Dr. C. P. J. Glaudemans of the National Institute of 
Allergy and Infectious Disease. 
(f)  HyX24-14 was purified from crude ascites  by affinity chromatography over an X24- 
Sepharose-4B column and elution with 3 M ammonium thiocyanate and rapid dialysis against 
PBS. 
Results 
Generation of HyX24-14.  1.75  ×  10  s  spleen  cells  of a  single  A/J  mouse  hyperim- 
munized with X24 myeloma protein were fused with Sp 2/0 cells and grown in  141 
individual cultures.  14 d after fusion, 115 cultures contained growing hybridoma cells, 
and  ~1  out  of  1.5  ×  106  spleen  cells  had  been  successfully  fused.  To  search  for 
monoclonal antibodies with specificity for GalBMP, the supernatants  of 45 growing 
cultures were screened for the presence of mouse IgM or IgG that would bind to 12si- 
X44  in  a  solid-phase  RIA.  In  this  procedure,  we  selected  only  for  cross-specific 
monoclonal antibodies. 
17 (38%) of these supernatants  had more than three times the binding (1,200 epm) 
activity  as  compared  with  supernatants  from cultures  without  growing hybridoma 
cells (400 epm). Eight positive cultures were cloned by limiting dilution in suspension 
culture. All eight hybridomas gave rise to growing clones, but only from five were we 
able to derive clones with X44 binding activity in the supernatant.  Further specificity 
testing of the  cloned  hybrids  showed that  four reacted  with  BALB/e IgA proteins. 
These hybridomas (HyX24-13, 16,  18, and  19), which recognize allotypic specificities, 
will be discussed in detail elsewhere.  The fifth hybridoma antibody, HyX24-14, will 
be the subject of the remainder of this paper. 
HyX24-14  was  subcloned  two  more  times.  Only  1  out  of  16  clones  tested  was PAWLITA ET  AL.  1949 
positive for X44 binding activity after the first subcloning, but after a second cloning 
cycle, 20 out of 20 clones tested were positive. Cells of one active subclone were grown 
up in mass culture and used for ascites production in pristane-eonditioned CAF1 mice. 
HyX24-14 was shown to be an IgG-1 protein by using individual heavy chain class- 
specific rabbit antisera. 
Specificity of the HyX24-14 Monoclonal Antibody.  In screening tests, a  standard prep- 
aration of HyX24-14 ascites was prepared and used throughout. A dilution of HyX24- 
14 ascites was allowed to fix to the solid substratum and an 125I target was added. The 
highest dilution that gave near-maximal counts bound was u~ed. When 125I-X24 was 
the target, a  1:50,000 dilution of the HyX24-14 ascites was used. Nine GalBMP  and 
three myeloma proteins that  did not  bind  galactan were  tested  for their ability to 
compete in the HyX24-14/X24 system (Table I, Fig. 1).  7.2 ng of cold X24 and 2,800 
ng of X44 gave 50%  control binding but  no other protein competed in this system. 
HyX24-I4 was most specific for X24 and appeared to bind to X24 with the highest 
affinity. X44 gave 50% control binding at ~400 times the concentration of X24. 
Specificity of the HyX24-14  Monoclonal Antibody in  the Hy-X24-14/X44  System.  The 
binding  of HyX24-14  to  X44  was  strong  enough  to  permit  the  construction  of a 
second RIA system in which the standard preparation of HyX24-14 was diluted  1: 
20,000  and  x2SI-X44 was the target  (Table I, Fig. 2).  In this system, 0.75  ng of X24 
and 9 ng of X44 gave 50% control binding; furthermore, S 10, T 191, T601, and T 1084 
weakly interacted.  From  these  two  RIA systems we conclude  that  the  monoclonal 
antibody  HyX24-14  has  a  specific  idiotypic  structures  common  to  some  of  the 
GalBMP. The relative affinity is highest for X24, medium for X44, low for S 10, T 191, 
T601, and T1084, and nondetectable for J 1, C4, J539, and three non-GalBMP. 
TABLE  I 
Specificity of Monoclonal (HyX24-14) and Conventional Antibodies to X24 
for Other GalBMP 
Competitors 
Competitor that gives  50% control binding 
Monoclonal  Monoclonal  Conventional 
HyX24/X24  HyX24-14/  a-X24/X24 
1:50,000  X44 1:20,000  1:80,000 
nanograms per 20 liters 
GalBMP  J 1  --:[:  --  -- 
C4  --  --  -- 
SI0  --  2,500  -- 
X24  7.2*  0.75  9.5 
X44  2,800  9  -- 
T191  --  2,900  -- 
J539  --  --  -- 
T601  --  1,100  12,000 
T 1084  --  1,800  18,000 
Non-GalBMP  El09  --  --  -- 
M167  --  --  -- 
T15  --  --  -- 
* Nanograms per 20 p.l. 
:[: No competition with 20,000 ng. 
The data reported represent typical data selected from at least three exper- 
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FIG.  I.  Radioimmune competition of the HyX24-14 monoclonal antibody for the X24 target. The 
standard HyX24-14 ascites preparation was diluted 1:50,000. O, X24; 0, X44; II, T539; A, T601. 
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FxG.  2.  Radioimmune competition of the HyX24-14 monoclonal antibody for the X44 target. The 
standard HyX24-14 ascites preparation was diluted 1:20,000. O, X24; O, X44; II, J539; A, T601. 
Hapten  Inhibition  Studies.  Four  oligosaccharides  were  tested  for  their  ability  to 
inhibit  the  binding of HyX24-14  to X44:  a-methyl-fl-D-galactoside (0-Me-Gal), ~- 
1,6-D-galactodiose (Gal2)  and fl-l,6-D-galactotriose (Gala) all bind to X24;  cellobiose 
was used as a negative control. As can be seen in Fig. 3, the Gala was the most potent 
inhibitor, Gal2 was more effective than O-Me-Gal, and cellobiose was inactive. These 
results indicate that specific haptens, even the monosaccharide alone, block the ability 
of HyX24-14 to bind to its complementary idiotope. 
Model  Building.  A  hypothetical  space-filled  model  of J539  has  been  described 
previously  (8).  This  was  constructed  by  modifying  the  coordinates  of  McPC603 
determined by x-ray crystallography (14).  The reconstruction process was done on an 
Evans & Sutherland  (Salt Lake City, Utah) viewing screen in stereo. J539  (and all of 
the other completely sequenced GalBMP) are  11  residues shorter than McPC603  (2- 
4). These length differences occur at three locations, CDR-1  VK, CDR-2, and CDR- 
3 VH.  The sites were located by sequence homology and the positions were deleted 
from the McPC603 structure. The open ends of the J539 structure were then rejoined 
by computer controls that permitted independent differential rotation ofamide planes PAWLITA ET AL.  1951 
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FIG. 3.  Hapten inhibition of the binding of HyX24-14 to X24 (--) and X44 (---).  II, Gall; O, Gal~; 
&, Gal3; O, cellobiose. 
in upstream or downstream residues. The entire process is recorded. To build models 
of X24, X44, and T601, the amino acid substitutions and deletions were first changed 
in the corresponding McPC603 and positions. Second, the backbones were rejoined 
exactly as was done with J539, using the same rotational angles. The joined sites were 
visually inspected on the screen. After the rejoining process, the structure was refined 
by a computer program (ANNEAL) that searched the space around each amino acid 
side chain  (one at a  time)  and  placed the side chain  in a  location with  no  illegal 
contacts with other side chains. All but  12 side chains could be placed in a  noncon- 
tacting location by this process, indicating that the molecule will have to be further 
refined. The hypothetical models, however, provide a plausible approximation of the 
relationship of side chains to each other, and a general contour map of the Fv surface. 
The front views ofJ539, X24, X44, and T601 are shown in Fig. 4. The amino acids 
of CDR-2 VH, the D region, and position 31 are shaded (Kabat number system) (15). 
The CDR-2 Vii region is formed by a bend-like structure that protrudes out on the 
front surface. There are three forms of this structure in the four GalBMP, as indicated 
by the amino acid sequence data  (Fig.  5).  X24 differs from the other GalBMP  in 
position  53  by Gly instead  of Asp.  The  negatively charged Asp  53  could  prevent 
HyX24-14 from strong binding to CDR-2 Vrt of X44, J539, and T601. The side chain 
of the D  region amino acid position (96 His or Gly) is very close to position 31  (Arg 
or  Lys).  In  X44,  Arg  31  and  His  96  form  a  unique  pair  not  found in  the  other 
GaIBMP (Fig. 4). 
Discussion 
In this study a monoclonal antibody (HyX24-14) was derived from an A/J mouse 
that  had been immunized with the X24 GalBMP. The initial screening procedure 
used to detect active clones used the X44 myeloma protein and thus favored selection 
of monoclonal antibodies with cross-specific binding properties. When the HyX24-14 
monoclonal antibody was tested for its ability to bind to a series of GalBMP whose V 
regions have been completely sequenced (2-4)  (Fig. 5), it was found that the affinity 
of HyX24-14 was highest for X24, medium for X44, low for T601, and nondetectable 
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Fro.  4.  Stereopictures of models of the Fv fragments of four GalBMP front view T601, X24, X44, 
and J539. The front surface faces the solvent and contains amino acid side chains that are implicated 
in  hapten  binding.  The VK domain  occupies about  the  left  half of the  Fv and  borders the  Vn 
domain on an angle of about 45 °. The shaded amino acids are: VH amino acids belonging to CDR- 
2 VH  (Kabat numbers 50-58)  and CDR-1  Vr~  (number 31). The CDR-3 Vn positions 96-97  are 
coded  by  the  D  region minigene.  The  pictures can  be  visualized  in  stereo  with  an  inexpensive 
stereoviewer sold  by  Hubbard Scientific  Co.,  Northbrook, Ill.  Representative  distances  between 
selected  atoms of X24 are NH1 Arg31  ~  OH Tyr98 =  13.7 A;  NH~ Arg31  ~  a  C  Gly 96  =  11.7 
A;  NZ Arg3l ~  a  C Gly 53~  I3.0 A;  OH Tyr 98---0 a  C  Gly 53  =  14.5 A;  CG Pro 52A ~  ND2 
Asn58 =  12.9 ,~. $10 
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Sequences of the GalBMP  were determined by Rao et al. (2, 3) and Rudikoff et al. (4). 
All of the binding studies were done by solid-phase competition assay systems. In 
this method, the antibody is fixed to the solid substratum and cold competitors are 
allowed to bind to the antibodies. The relative binding affinities are reflected in the 
amount of cold competitor that binds to the fixed antibody and competes with the 
labeled target. The smaller the amount needed of a given GalBMP to compete with 
the 12sI target antigen, the higher is the affinity to the antiidiotypic antibody. In the 
RIA system, where HyX24-14 was coated on the plate in the lowest concentration (1: 
50,000) and t~5I-X24 was the target, X24 had the highest affinity for HyX24-14 and 
the affinity of X44 was lower (400 times less potent). In a less specific assay system, 
where a higher concentration of HyX24-14 (1:20,000) was adhered to the plate and 
x25I-X44 was used as the target, X24 bound again with the highest affinity, X44 was 
10 times less potent, T601 was weak (1,500 times less potent), and binding ofJ539 
was not detectable at all. 
The availability of four GalBMP whose V regions have been completely sequenced 
and hypothetical molecular models that approximate the location of amino acids on 
the surface topography, enables us to propose a structural explanation for the observed 
binding activities of HyX24-14. 
JK  region  sequence  differences  should  not  directly  cause  the  observed  affinity 
difference for binding of the GalBMP to HyX24-14 because positions 96,  100,  and 
106 are inaccessible to the surface. Because X24 and T601 have identical L chains up 
to position  100L, sequence differences in Vn and D  are probably responsible for the 
affinity differences. Essentially, we propose that HyX24-14 interacts with a relatively 
large surface of the GalBMP that includes both parts of CDR-2 and the CDR-3 (the 
D region) of the H  chain. In the models, these regions project as two loop structures 
towards  the  solvent. These loops are  separated  by a  depression  (Fig.  4);  thus  the 
potential epitope can be divided into two subsites. The region contributing the larger 
part of the affinity for X24 is represented by the CDR-2 Vn subsite in the vicinity of 
53H. X24 in this region has an important primary structural change, i.e., a glycine at 
position 53H instead of aspartic acid. This substitution changes the local secondary 1954  IDIOTOPES OF GALACTAN-BINDING MYELOMA PROTEINS 
structure of the  CDR-2  loop  as  well  as  the  electrostatic properties.  Because T601 
differs from X24 in VH only at this position 53H (and two framework positions), we 
conclude that this region of the antibody surface is most important for the binding at 
X24 to HyX24-14. 
The ability of HyX24-14 to bind X44 with moderate affinity, even though X44 
also has the aspartic acid at position 53H, suggests the presence of a  second subsite 
that contributes to binding. One possibility would be that  there is a  second subsite 
present in X24 and X44 but absent in T601 and J539. Surprisingly, the amino acid 
sequence data show that  there are no shared primary structural similarities in X24 
and X44 that are absent in T601. To explain this phenomenon, we postulate from the 
sequence data and the models that X44 has a  unique structure in the region of this 
second subsite that binds HyX24-14 better than the corresponding structures in other 
GalBMP, including X24. The candidate amino acid combination for the second site 
is Arg 31H and His 96H in X44. The association of these two amino acids in X44 is 
unique  among  the GaIBMP,  and  for this  reason  probably determines this  second 
subsite.  Because X44 was  used  as the selecting antigen  during the  isolation of the 
hybridoma, this is not an unreasonable explanation. 
It is postulated that HyX24-14 is complementary to a  general contour formed by 
all of the GalBMP.  The contour of HyX24-14 would  appear to have a  projected 
structure that fits in the depression between CDR-2 VH and the 31H-96H complex. 
Binding affinity is determined by complementarity forces between groups on amino 
acids side chains of idiotype and anti-idiotype. Distances between amino acids on the 
GalBMP are shown in Fig. 4 (see legend). The distances between the a  carbon of Gly 
53H, the fl nitrogen of Arg 31H, and the a  carbon of Gly 96H in X24 are all ~ 13-14 
A apart. The area of contact between idiotype and antiidiotype might even be larger. 
The hapten fl-1,6-O-galactohexose was constructed and fitted to the frontal surface in 
such a way that the oxygens of the first, third, and fourth sugars made close contact 
with the hydrogen bond accepting amino acids in J539 (8). The binding site in J539 
thus involves amino acids in CDR-2 Vn. The terminal galactose residue binds very 
near to Trp 33 VH; thus the proposed CDR-2 VH subsite is neighboring the proposed 
hapten  binding site.  Even smaller haptens,  including  the  O-methyl-fl-D-galactoside 
are proposed to bind very near to Trp 33 Vn and are therefore expected to inhibit the 
binding of X24 and X44 to HyX24-14. The hapten inhibition studies show that even 
the methylated monosaccharide can  inhibit  this binding.  The presence of separate 
subsites, as suggested by the data, could provide two dissociated binding sites.  Thus, 
a  series of homogenous  antibodies  with  the  similar  but  not  identical  structure  of 
HyX24-14 could bind  to either epitope independently or, unlike  HyX24-14, could 
bind to both subsites with equal energy. In antibody protein interactions, single amino 
acids can have profound effects. Thus, somatic mutations affecting such antibody sites 
could give rise to novel binding properties. 
The concept of two subsites being recognized by HyX24-14 could also explain the 
apparent  difference of the  idiotype defined by conventional anti-idiotypic sera  (a- 
X24-IdI) and the idiotype defined by the monoclonal anti-idiotypic antibody (HyX24- 
14) (Table I). The a-X24 serum contains specific antibodies from a pool of individual 
clones. These antibodies would all recognize the epitope subsite formed by CDR-2H 
(7).  In addition, each clonal product would be able to bind some structures in the 
environment of this subsite. Antibodies of the HyX24-14 clonotype probably are also PAWLITA ET AL.  1955 
present in the conventional a-X24 serum, but in such a  low concentration that the 
RIA could detect neither direct binding of 1~I-X44 no competing activity of X44 in 
the a-X24/X24 system. However, in the HyX24-14/X24 system, all antibodies are of 
identical specificity, i.e., they bind the same part of the environment around CDR- 
2H in identical fashion. Thus, direct binding of lzSI-X44  and competing activity of 
X44 in the HyX24-14/X24 system could be detected. 
Because the anti-idiotypic antibody can bind to an area larger than the epitope 
subsite, even small changes in the structure of the subsite environment could enhance 
or lower the affinity. In a conventional antiserum this would not be detectable because 
binding of only a small percentage would be influenced by this change, whereas the 
affinity of a monoclonal antibody could fully reflect this change when it covers this 
part  of the  subsite  environment.  This  phenomenon  might  explain  some  of the 
unexpected  findings  when  conventionally defined antigens  were  "redefined" with 
monoclonal antibodies (16). 
The proposed subsites  are determined by different gene elements, e.g,  D  region 
codons  and  VH  codons  that  are  expressed  independently.  A  series  of clonotypes 
expressing VH 1B and VK4 genes that elaborate fl-1,6-o-galactan-binding specificity 
could manifest a variety of structures determined by JK, Jn, and D exons that change 
the idiotypic antigenicity. Schilling et al. (17) have shown in the a-1,3 dextran system 
that  a  variety  of a-l,3  dextran  binding  proteins  with  different  D  exons  can  be 
generated in the BALB/c mouse. The GalBMP reflect a similar pattern. Monoclonal 
idiotypic antibodies that enhance or suppress immune responses (18, 19) could modify 
some clonotypes in a given response without involving other closely related structures. 
Much  more  information  is  needed  on  the  binding  specificities  of antiidiotypic 
antibodies  to  provide  a  better  basis  for understanding  and  controlling biological 
actions of anti-idiotypic antibodies. 
Summary 
An  IgG1  monoclonal antibody HyX24-14 was  derived from A/J  mice that  were 
immunized  with  the  IgA  XRPC24  0(24)  galactan  binding  myeloma  protein 
(GalBMP) of BALB/c origin by the Kohler-Milstein hybridoma technology. HyX24- 
14 specifically binds some but not all GalBMP. Different patterns of binding using a 
panel of nine GalBMP were found, depending upon the concentration of antibody 
and the antigenic target. From molecular models and amino acid sequence data, it 
was proposed that the idiotope defined by HyX24-14 had two subsites, each of which 
appeared to be able to bind independently to the antibody. 
Received for publication 24July  1981. 
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